McKesson Nears $1,000 With Insiders Selling Into the Rally

McKesson reports fiscal second-quarter results on November 4, trading at $994.58 after a 15% surge over the past month that has left the stock within touching distance of the $1,000 mark. While analysts have been lifting their targets and retail attention has spiked, the insider register tells a quieter story: net selling of roughly $1.2 million across the past 90 days, with the most recent trade a planned sale by the company's CIO and CTO in mid-October.

That insider activity is worth keeping in perspective. Every sale on record was executed under a pre-arranged 10b5-1 plan, which means the trades reflect scheduled liquidations rather than real-time conviction. CEO Brian Tyler sold over $17 million worth of shares across three tranches between June and July, all under plan, as the stock climbed from the $760s toward $800. The pattern suggests routine compensation management rather than a bearish read on the quarter, but the absence of any open-market buying into a 15% monthly rally is a notable gap.

The analyst community has been more vocal about upside. UBS raised its target to $1,200 from $1,080 on October 16, the most aggressive call in the recent batch. Mizuho moved to $1,020 from $905 while staying at Neutral, and Leerink Partners lifted to $1,070. The consensus mean of $1,026 now sits just 3% above the current price, a narrow implied return after October's move. The core bull argument is structural: specialty drugs are heading toward 55% of total drug spending by 2028, biosimilars could add around $250 million of operating income by that year, and McKesson's distribution scale positions it to capture an outsized share. Bears point to a specific pressure point: GLP-1 prior authorizations account for roughly $560 to $660 million of revenue, and employer coverage of those drugs is contracting. Add potential Maximum Fair Price negotiations on approximately $28 billion of Medicare drug spend from 2028 onward, and the path to 11 to 15% operating income growth requires either mid-teens BioPharma Solutions growth or meaningful margin expansion.

Positioning across the lending market and options desk gives no particular signal either way. Short interest is low at 1.8% of the free float and has drifted down 2% over the past week. Borrow costs are minimal at 0.28%, down sharply over the past month, and availability is essentially unlimited, meaning there is no squeeze pressure and no structural bet against the stock. The put/call ratio at 0.81 sits less than one standard deviation above its 20-day average, nowhere near the defensive extremes seen earlier in the year when it reached 1.18. Medicaid units reimbursed through McKesson's channels rose 78% year on year in the first quarter of 2026 and have increased for three consecutive quarters, a sign of volume momentum in the government channel, though no measured link to reported revenue has been established.

The November 4 print is therefore less a test of whether McKesson is growing and more a question of whether the mix of that growth, specialty volumes, GLP-1 exposure and oncology distribution, is translating into margin improvement at a pace that justifies a stock now priced at 20 times earnings and trading at record levels.